BiologicalDrug
Baminercept clinical trials
Also written BG9924.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
8 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 4 |
| 2010 | 2 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Biogen (6) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Zurich (1)
Often tested with
Tested in the same studies.
Recombinant Lymphotoxin Beta (1) · Lymphotoxin-Beta (1)
Studies
Open first, then newest update. How each study uses baminercept is read from its arms, and is right about nine times in ten.
Testing it · 8
- Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's SyndromeTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01552681Written as Baminercept
- Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) ParticipantsCompletedPhase 2BiogenNCT00664716Written as Baminercept alfa 1
- 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) ParticipantsTerminatedPhase 2BiogenNCT00664573Written as Baminercept alfa (BG9924)
- BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid ArthritisTerminatedPhase 2BiogenNCT00458861Written as BG9924
- BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)TerminatedPhase 2BiogenNCT00523328Written as BG9924
- Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnPhase 1/2BiogenNCT01181089Written as Baminercept
- A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.Status unknownPhase 1University of ZurichNCT01164384Written as Baminercept
- Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid ArthritisCompletedPhase 2BiogenNCT00292422Written as BG9924
Codes
What other systems call baminercept · ClinicalTrials.gg INT000273
- MeSH (NLM) C000599771baminerceptOne source NLM
- UNII (FDA) HTV56CD308BAMINERCEPTConfirmed FDA, NLM, Wikidata
- Wikidata Q106728191baminerceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96762Baminercept AlfaOne source FDA
- DrugBank DB06576One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599771 | baminercept | One source NLM |
| UNII (FDA) | HTV56CD308 | BAMINERCEPT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q106728191 | baminercept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96762 | Baminercept Alfa | One source FDA |
| DrugBank | DB06576 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.